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Objectives This trial sought to assess the influence of omeprazole on clopidogrel efficacy.
Background Clopidogrel has proved its benefit in the treatment of atherothrombotic diseases. In a previous observational
study, we found clopidogrel activity on platelets, tested by vasodilator-stimulated phosphoprotein (VASP) phos-
phorylation, to be diminished in patients receiving proton pump inhibitor (PPI) treatment.
Methods In this double-blind placebo-controlled trial, all consecutive patients undergoing coronary artery stent implanta-
tion received aspirin (75 mg/day) and clopidogrel (loading dose, followed by 75 mg/day) and were randomized
to receive either associated omeprazole (20 mg/day) or placebo for 7 days. Clopidogrel effect was tested on
days 1 and 7 in both groups by measuring platelet phosphorylated-VASP expressed as a platelet reactivity index
(PRI). Our main end point compared PRI value at the 7-day treatment period in the 2 groups.
Results Data for 124 patients were analyzed. On day 1, mean PRI was 83.2% (standard deviation [SD] 5.6) and 83.9%
(SD 4.6), respectively, in the placebo and omeprazole groups (p  NS), and on day 7, 39.8% (SD 15.4) and
51.4% (SD 16.4), respectively (p  0.0001).
Results Omeprazole significantly decreased clopidogrel inhibitory effect on platelet P2Y12 as assessed by VASP phos-
phorylation test. Aspirin-clopidogrel antiplatelet dual therapy is widely prescribed worldwide, with PPIs frequently
associated to prevent gastrointestinal bleeding. The clinical impact of these results remains uncertain but merits
further investigation. (OCLA: Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated to As-
pirin; http://www.clinicaltrials.gov/ct2/show/NCT00349661; NCT00349661) (J Am Coll Cardiol 2008;51:
256–60) © 2008 by the American College of Cardiology Foundation











ulatelet activation and aggregation play an important role in
he pathogenesis of arterial thrombosis and lead to acute
oronary syndrome and complications during and after
ercutaneous coronary intervention. Clopidogrel, a thieno-
yridine, inhibits platelet activation induced by adenosine
iphosphate (ADP). Alone or in association with aspirin,
lopidogrel has successfully proved its benefit in the treat-
ent of atherothrombotic disease (1,2). It also decreases the
ncidence of coronary artery stent thrombosis (2).
Clopidogrel is a prodrug, and must be metabolized in
he liver to acquire its antiaggregation properties. Clopi-
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nd Chest Diseases, Brest University Hospital, Brest, France. Drs. Abgrall and
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ccepted June 12, 2007.ogrel requires several biotransformation steps, mediated
ainly by cytochrome P-450 isoenzymes, to generate
n active metabolite. It exerts its antiplatelet effect by
orming an inactivating disulfide bond with the platelet
2Y12 ADP receptor. Clopidogrel inhibits the effect of
See page 261
DP on the P2Y12 receptor. This is associated with
ephosphorylation of intraplatelet vasodilator-stimulated
hosphoprotein (VASP). Vasodilator-stimulated phos-
hoprotein phosphorylation provides an index of platelet
eactivity to clopidogrel: the higher the platelet reactivity
ndex (PRI), the more frequently thrombosis occurs
nder clopidogrel (3).
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4,5). The isoenzyme CYP2C19 seems to be one of the
eterminants of the pharmacodynamic response to clopi-
ogrel (6), and is also involved in the metabolism of proton
ump inhibitors (PPIs), such as omeprazole (7). Patients
eceiving clopidogrel and aspirin dual therapy after coronary
tenting are commonly treated with PPIs.
We previously showed in an observational study of 105
onsecutive patients that PPI users had significantly higher
RI values (8). Our hypothesis is that PPIs reduce the
iological action of clopidogrel, probably by competitive
etabolic effects on CYP2C19. The aim of the present
rospective, randomized, double-blind study was to assess
hether the action of clopidogrel would be reduced in
atients receiving associated omeprazole treatment.
ethods
atients and study protocol. We conducted a prospective,
ouble-blind, placebo-controlled, randomized trial. All
onsecutive patients undergoing elective coronary stent
mplantation were considered for inclusion. They received
spirin (75 mg/day) and clopidogrel (loading dose 300 mg,
ollowed by 75 mg/day). After written informed consent
as obtained, patients were randomized to 2 treatment
roups: associated 20 mg/day omeprazole or placebo, for 7
ays.
Exclusion criteria were previous treatment with clopi-
ogrel or PPI, history of thrombocytopenia (150,000
latelets/ml) or bleeding disorder, liver disease, gastrointes-
inal ulcer, or pregnancy.
Patients were documented for atherosclerosis risk factors.
oncomitant cardiovascular medication—statins, beta-
lockers, or angiotensin-converting enzyme inhibitors—at
nclusion was also recorded. The institutional review board
pproved the study protocol.
latelet reactivity. Blood samples were collected on so-
ium citrate on Day 1 before the loading dose of clopi-
ogrel, and 7 days afterward. Laboratory physicians per-
ormed VASP phosphorylation analysis blinded to
reatment group and to whether the sample was from Day 1
r Day 7. Platelet reactivity was assessed by measuring
latelet-phosphorylated VASP in whole blood using a new
ommercially available Platelet VASP kit (Biodis-Stago,
snières, France) adapted from the method of Schwartz
t al (9). Briefly, after initial incubation with prostaglandin
1 (PGE1) with or without 10 mol/l ADP, platelets were
xed. The second stage consists of coupling phosphorylated
ASP with a monoclonal fluorescein isothiocyanate–labeled
ntibody specific to the phosphorylated form of VASP.
latelet mean fluorescence intensity (MFI) was then deter-
ined using a flow cytometer counting 10,000 platelets.
latelet reactivity was expressed as a PRI calculated as:
PRI% (MFI [PGE1]
MFI PGE1ADP)/MFI PGE1 100his ratio is expressed as mean
ercentage platelet reactivity, in-
ersely correlated with clopidogrel
reatment efficiency. According to
he criteria of Barragan et al. (3),
atients are good responders to
lopidogrel if PRI is 50% and
oor responders if PRI is 50%.
tatistics. The number to treat
as estimated on the basis of our
revious observational study (8).
e estimated that a study sam-
le size of 120 would enable a
ne-half standard deviation (SD)
ifference (i.e., a 10% difference
n PRI between groups) to be detected, with an 80%
tatistical power and a 5% alpha risk. To ensure that this
ample size would be available for analysis, 20 extra patients
ere randomized and included.
The characteristics of the 2 groups were compared using
hi-square tests for qualitative and t tests for continuous
ariables. The main end point compared the PRI value at
he 7-day treatment period in the 2 groups by a Student t
est. The secondary end points were the PRI variation
uring the 7-day treatment period in the 2 groups and a
hi-square comparison of the proportion of patients with
-Excluded (n= 214) 
-Not meeting inclusion criteria: (n=197) 
• Previous treatment with 
clopidogrel (n=158) 
• Previous treatment with 
PPI(n=39)
-Refused to participate: (n=17) 
Randomization (n=140)
Enrollment








Assessed for eligibility (n=354) 
Allocation
-Lost to follow-up 
• No Day 7 blood sample (n= 1) 
-Discontinued intervention
• Consent withdrawal (n= 4) 
-Serious adverse event
• In stent thrombosis (n= 1) 
-Lost to follow-up 
• No Day 7 blood sample (n= 4) 
-Discontinued intervention
• Consent withdrawal (n= 4) 
-Serious adverse event
• In stent thrombosis (n= 1) 
Follow-Up
-Analyzed (n=64) -Analyzed (n=60) 
-Excluded from analysis (n= 1) 
• Previous missed PPI 
treatment
Analysis
Figure 1 Consort Statement and Flow Diagram
From 354 eligible patients, 140 were included. Finally, 64 patients were ana-






MFI  mean fluorescence
intensity
PPI  proton pump
inhibitor
PRI  platelet reactivity
index
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Omeprazole and Clopidogrel Efficacy January 22, 2008:256–60RI below 50% in the 2 groups (3). A value of p 0.05 was
onsidered statistically significant. Statistical analysis was
erformed blind to randomization group.
Figure 2 Mean PRI on Days 1 and 7 in the Two Groups
On Day 1, mean platelet reactivity index (PRI) was 83.2% and 83.9%,
respectively, in the placebo and omeprazole groups (nonsignificant). On
Day 7, mean PRI was 39.8% and 51.4%, respectively, in the placebo and
omeprazole groups (p  0.0001). VASP  vasodilator-stimulated
phosphoprotein.
atient Baseline Characteristics and Treatments




(n  64) p
Characteristics
Age (yrs) 63.67 12.22 62.28 15.04 NS
Male gender 45 (75%) 52 (81.3%) NS
Smoker 43 (71.7%) 41 (64.1%) NS
Hypertension 32 (47.1%) 36 (52.9%) NS
Family history of CAD 26 (43.3%) 22 (34.4%) NS
Diabetes mellitus 11 (18.3%) 6 (9.4%) NS
Body mass index (kg/m2) 27.51 4.3 26.66 4.7 NS
Dyslipidemia 43 (71.6%) 42 (65.6%) NS
Previous MI 5 (8.3%) 7 (10.9%) NS
Treatment
Beta-blocker 58 (90.6%) 50 (83.3%) NS
ACE inhibitor 32 (50%) 29 (48.3%) NS
Atorvastatin 41 (68.3%) 43 (67.2%) NS
Other statin 18 (28.1%) 14 (23.3%) NS
CE angiotensin-converting enzyme; CAD coronary artery disease; MImyocardial infarction;
S  not significant.esults
etween July 2006 and November 2006, 354 patients were
ssessed for eligibility. Following predetermined exclusion
riteria, 140 patients were included and randomized, 70 in
he omeprazole group and 70 in the placebo group. The
atient flowchart is shown in Figure 1. No patient was lost
o follow-up. Data for 16 of the 140 patients were not
nalyzed: 1 was receiving PPIs at inclusion, 5 failed to
eturn on Day 7 for blood sampling (they had no adverse
vents); 8 excluded themselves from the study, using their
ight to withdraw consent; and 2 experienced a serious
dverse event (2 in-stent thromboses, both on Day 4, 1 in
ach group). No other serious adverse event was noted.
inally, 64 patients were analyzed in the omeprazole group
nd 60 in the placebo group.
Baseline characteristics were similar in the 2 groups
Table 1). On Day 1 the mean PRI was similar, 83.2% (SD
.6) and 83.9% (SD 4.6), and on Day 7 the mean PRI was
9.8% (SD 15.4) and 51.4% (SD 16.4), respectively, in the
lacebo and omeprazole groups (p  0.0001) (Fig. 2). The
ean PRI variation was 43.3% (SD 15.9) and 32.6%
SD 16.4), respectively, in the placebo and omeprazole
roups (p  0.0001) (Fig. 3).
On Day 7, 16 patients (26.7%) were poor responders in
he placebo group compared with 39 (60.9%) in the ome-
razole group (p  0.0001). The odds ratio of being a poor
esponder to clopidogrel when concomitantly treated with
meprazole was 4.31 (95% confidence interval 2.0 to 9.2).
iscussion
n this double-blind, placebo-controlled, randomized trial,
meprazole significantly decreased the effect of clopidogrel
n platelet activation as tested by VASP phosphorylation.
Figure 3 Variation of Platelet Reactivity Index
The platelet reactivity index (PRI) decrease was 43.3% in the placebo group
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January 22, 2008:256–60 Omeprazole and Clopidogrel Efficacylatelet function test. After percutaneous coronary inter-
ention or acute coronary syndrome, clopidogrel–aspirin
ual therapy has become the standard antiplatelet manage-
ent approach (1,2). Previous studies indicated that clopi-
ogrel resistance might indicate increased risk of cardiovas-
ular event recurrence (3,10). The mechanisms underlying
lopidogrel resistance are still controversial. Possible expla-
ations include increased reactivity in remaining platelets,
enetic polymorphisms of the ADP receptor, differences in
esorption, or a combination of these factors (4,5,11).
ysfunctional cytochrome P450 metabolism has also been
hown when clopidogrel was associated with various drugs
uch as atorvastatin (4,12). However, no such significant
ffect emerged in further placebo-controlled studies (13,14).
Standard platelet aggregometry measures the inhibition
f ADP-induced aggregation (15). Other methods include
easuring fibrinogen binding or platelet adhesion, moni-
oring platelet activation. These general platelet function
ndices are relatively unspecific and are of limited clinical use
ecause patients typically receive several drugs affecting
latelet function (e.g., aspirin) concomitantly. Analysis of
ASP phosphorylation is more reliable than previous assays
or quantifying clopidogrel effects, with a high measurement
recision and reproducibility (16,17). Because the VASP
ssay directly measures the function of the clopidogrel target
the P2Y12 receptor), it is selective for thienopyridine
ffects and is not affected by other commonly used platelet
nhibitors such as aspirin (16). Potential benefits of VASP
easurements would be helpful for multicenter trials and
ontrast with unspecific platelet function measurements that
re usually performed.
otential clinical impact. The clinical implications of our
esults remain uncertain but merit further investigation. The
ASP assay or other techniques showed wide variability in
he inhibitory platelet response to clopidogrel, with one-
hird of the patients appearing to be unprotected (15,17,18).
uch heterogeneity may have important clinical implica-
ions (3,10). In patients undergoing percutaneous coronary
ntervention, Matetzky et al. (10) found ADP-induced
latelet activation to be highly predictive of secondary acute
ardiovascular events: 40% of patients in the first quartile of
eduction experienced a recurrent cardiovascular event dur-
ng 6-month follow-up, versus only 1 patient (6.7%) in the
econd and none in the third and fourth quartiles. Barragan
t al. (3) showed that patients were protected if they had a
ASP phosphorylation rate (PRI) 50%. A strong corre-
ation between VASP test results and subacute coronary
tent thrombosis was found. In our study, 60.9% of patients
ndergoing omeprazole therapy showed a PRI 50% (poor
esponders), compared with only 26.7% in the placebo
roup (odds ratio 4.31).
lopidogrel, PPIs, and cytochrome P4502C19. The ac-
ive metabolite of clopidogrel, which irreversibly blocks
latelet ADP P2Y12 receptors, arises from complex bio-
hemical reactions involving several CYP isoforms (19). Lau
t al. (11) reported that CYP3A4 metabolic activity corre-ated with between-subject variability in clopidogrel
esponsiveness.
The PPIs are eliminated by the hepatic route, and the
olymorphically expressed CYP2C19 is involved in the
etabolism of omeprazole, lansoprazole, rabeprazole, es-
meprazole, and pantoprazole (7). As with clopidogrel,
enotypic differences in CYP2C19 status affect the action of
PIs (20).
onclusions
n this randomized study, omeprazole significantly decreased
he effect of clopidogrel on platelet as tested by VASP
hosphorylation. Aspirin–clopidogrel antiplatelet dual ther-
py is widely prescribed worldwide, with PPIs frequently
ssociated to prevent gastrointestinal bleeding. The clin-
cal impact of these results must be assessed by further
nvestigations, but we recommend not adding systemat-
cally a PPI treatment to the antiplatelet dual therapy
ithout formal indication.
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